-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 14, Shanghai Pharmaceutical announced that the application for the clinical trial of SPH5030 tablets was accepted, and it was intended to be used for the treatment of advanced solid tumors
.
SPH5030 is a new type of small molecule inhibitor, independently developed by Shanghai Pharmaceuticals, the company owns complete intellectual property rights
.
It is intended for the treatment of advanced solid tumors
.